Consistently, our data suggested that Srx acted as a multi-regulator by reducing the hyperoxidized PrxI, PrxII, and PrxIII proteins, and thus is a prospective therapeutic target against incurable colon cancer. Here, PRDX1 is linked to colonic neoplasm.